WST Stock Analysis: West Pharmaceutical | NYSE
Medical Instruments & Supplies | NYSE, USA | Market Cap: 26.292m USD | 12M Return: 34% | US9553061055 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 211M
EPS Trend: 3.6%
Qual. Beats: 6
Rev. Trend: 77.3%
Qual. Beats: 2
Warnings
No concerns identified
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
West Pharmaceutical Services, Inc. (NYSE: WST) is a global manufacturer of containment and delivery systems for injectable drugs and healthcare products, operating across the Americas, Europe, the Middle East, Africa, and Asia Pacific. Founded in 1923 and headquartered in Exton, Pennsylvania, the company runs two segments: Proprietary Products, which includes stoppers, seals, syringe and cartridge components, drug reconstitution and transfer technologies, self-injection devices, and packaging-related services for biologic, generic, and pharmaceutical drug companies; and Contract-Manufactured Products, which provides design, manufacturing, and automated assembly of devices for surgical, diagnostic, ophthalmic, and other drug delivery applications. Products are sold through a direct sales force, distribution network, contract sales agents, and regional distributors.
The company sits within the Health Care Supplies sub-industry, supplying critical primary packaging components (such as elastomer stoppers and seals) that are integral to injectable drug safety and sterility, often embedded in long-term supply agreements with pharmaceutical manufacturers. As a large-cap player in its segment, WSTs business model is anchored to the growth of biologics and complex injectable therapies, where high regulatory and quality barriers limit competition and support pricing power.
- GLP-1 and biologic injectable drug demand lifts Proprietary Products revenue
- Contract-Manufactured segment pressured by customer inventory destocking
- High-value product mix shift supports operating margin expansion
| Net Income: 564.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA 2.02 > 1.0 |
| NWC/Revenue: 35.08% < 20% (prev 36.36%; Δ -1.28% < -1%) |
| CFO/TA 0.16 > 3% & CFO 662.2m > Net Income 564.9m |
| Net Debt (-14.5m) to EBITDA (867.9m): -0.02 < 3 |
| Current Ratio: 2.82 > 1.5 & < 3 |
| Outstanding Shares: last quarter (71.3m) vs 12m ago -2.06% < -2% |
| Gross Margin: 36.77% > 18% (prev 35.32%; Δ 1.44% > 0.5%) |
| Asset Turnover: 82.86% > 50% (prev 74.88%; Δ 7.98% > 0%) |
| Interest Coverage Ratio: 69.34 > 6 (EBIT TTM 686.5m / Interest Expense TTM 9.90m) |
| A: 0.29 (Total Current Assets 1.81b - Total Current Liabilities 640.5m) / Total Assets 4.08b |
| B: 1.13 (Retained Earnings 4.62b / Total Assets 4.08b) |
| C: 0.17 (EBIT TTM 686.5m / Avg Total Assets 4.01b) |
| D: 2.75 (Book Value of Equity 2.99b / Total Liabilities 1.09b) |
| Altman-Z'' = 9.62 = AAA |
| DSRI: 1.09 (Receivables 712.0m/582.4m, Revenue 3.33b/2.96b) |
| GMI: 0.96 (GM 35.32% / 36.77%) |
| AQI: -2.36 (AQ_t -0.27 / AQ_t-1 0.11) |
| SGI: 1.12 (Revenue 3.33b / 2.96b) |
| TATA: -0.02 (NI 564.9m - CFO 662.2m) / TA 4.08b) |
| Beneish M = -4.90 (Cap -4..+1) = AAA |
As of October 03, 2026, the stock is trading at USD 364.98 with a total of 471,913 shares traded. Over the past week, the price has changed by -1.47%, over one month by +6.52%, over three months by -0.14% and over the past year by +34.03%.
Current recommended Stop Loss: 355.70 (which is 2.5% or 1.1 ATR below the current price).
West Pharmaceutical has received a consensus analysts rating of 4.69. Therefore, it is recommended to buy WST.
- StrongBuy: 10
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 407.6 | 11.7% |
P/E Trailing = 47.7749
P/E Forward = 37.037
P/S = 7.9032
P/B = 6.7059
P/EG = 3.4316
Revenue TTM = 3.33b USD
EBIT TTM = 686.5m USD
EBITDA TTM = 867.9m USD
Long Term Debt = 202.9m USD (from longTermDebt, last quarter)
Short Term Debt = 20.9m USD (from shortTermDebt, last quarter)
Debt = 421.3m USD (from shortLongTermDebtTotal, last quarter) + Leases 109.2m
Net Debt = -14.5m USD (calculated: Debt 421.3m - CCE 435.8m)
Enterprise Value = 26.3b USD (26.3b + Debt 421.3m - CCE 435.8m)
Interest Coverage Ratio = 69.34 (Ebit TTM 686.5m / Interest Expense TTM 9.90m)
EV/FCF = 60.15x (Enterprise Value 26.3b / FCF TTM 436.9m)
FCF Yield = 1.66% (FCF TTM 436.9m / Enterprise Value 26.3b)
FCF Margin = 13.13% (FCF TTM 436.9m / Revenue TTM 3.33b)
Net Margin = 16.98% (Net Income TTM 564.9m / Revenue TTM 3.33b)
Gross Margin = 36.77% ((Revenue TTM 3.33b - Cost of Revenue TTM 2.10b) / Revenue TTM)
Gross Margin QoQ = 37.74% (prev 35.08%)
Tobins Q-Ratio = 6.45 (Enterprise Value 26.3b / Total Assets 4.08b)
Interest Expense / Debt = 2.35% (Interest Expense 9.90m / Debt 421.3m)
Taxrate = 20.61% (144.2m / 699.6m)
NOPAT = 545.0m (EBIT 686.5m * (1 - 20.61%))
Current Ratio = 2.82 (Total Current Assets 1.81b / Total Current Liabilities 640.5m)
Debt / Equity = 0.14 (Debt 421.3m / totalStockholderEquity, last quarter 2.99b)
Debt / EBITDA = -0.02 (Net Debt -14.5m / EBITDA 867.9m)
Debt / FCF = -0.03 (Net Debt -14.5m / FCF TTM 436.9m)
Total Stockholder Equity = 3.05b (last 4 quarters mean from totalStockholderEquity)
RoA = 14.07% (Net Income 564.9m / Total Assets 4.08b)
RoE = 18.51% (Net Income TTM 564.9m / Total Stockholder Equity 3.05b)
RoCE = 21.09% (EBIT 686.5m / Capital Employed (Equity 3.05b + L.T.Debt 202.9m))
RoIC = 16.56% (NOPAT 545.0m / Invested Capital 3.29b)
WACC = 7.00% (E(26.3b)/V(26.7b) * Re(7.08%) + D(421.3m)/V(26.7b) * Rd(2.35%) * (1-Tc(0.21)))
Discount Rate = 7.08% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -93.87 | Cagr: -1.82%
[DCF] Terminal Value 77.97% ; FCFF base≈399.7m ; Y1≈458.2m ; Y5≈674.4m
[DCF] Fair Price = 144.4 (EV 10.1b - Net Debt -14.5m = Equity 10.2b / Shares 70.4m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 3.64 | EPS CAGR: 0.34% | SUE: 1.46 | # QB: 6
Revenue Correlation: 77.26 | Revenue CAGR: 4.09% | SUE: 1.17 | # QB: 2
EPS current Quarter (2026-09-30): EPS=2.19 | Chg30d=+0.14% | Revisions=+75% | Analysts=13
EPS current Year (2026-12-31): EPS=8.96 | Chg30d=+0.04% | Revisions=+82% | GrowthEPS=+22.9% | GrowthRev=+9.8%
EPS next Year (2027-12-31): EPS=9.98 | Chg30d=+0.18% | Revisions=+82% | GrowthEPS=+11.4% | GrowthRev=+6.3%
[Analyst] Revisions Ratio: +92% (up=37, down=0)